Azaindoles having serotonin receptor affinity
Described herein are compounds with affinity for the 5-HT 6 receptor, which have the general formula I: Wherein A, B, D, E, R 1 to R 3 and n are described herein. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT 6 receptor is implicated, such as schizophrenia.
1. A compound according to Formula:
or a salt or hydrate thereof, wherein
one of A, B D or E is a N atom, the remainder being CH groups;
R 1 is selected from the group consisting of SO 2 Ar, C(O)Ar, CH 2 Ar and Ar;
R 2 and R 3 are independently selected from the group consisting of H and alkyl;
represents a single or double bond, with the proviso that there is only one double bond in the ring at a time;
n is an integer of from 1-3; and
Ar is an optionally substituted 5-10 membered mono or bi-cyclic group which can contain up to 2 heteroatoms selected from O, N, and S, wherein the optional substituents are independently selected from 1-4 members of the group consisting of halo, hydroxy, alkyl, alkoxy, thioalkyl, trifluoromethyl and trifluoromethoxy.
2. A compound according to claim 1 wherein R 1 is selected from the group consisting of SO 2 Ar and C(O)Ar.
3. A compound according to claim 1 wherein R 1 is SO 2 Ar.
4. A compound according to claim 3 wherein Ar is selected from the group consisting of substituted phenyl and naphthyl.
5. A compound according to claim 4 wherein Ar is naphthyl.
6. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and, in an amount effective to antagonize the 5-HT 6 receptor, a compound of claim 1 .
7. A method for treating a patient having a medical condition for which a 5-HT 6 antagonist is indicated, comprising the step of administering to the patient a pharmaceutical composition comprising a compound of claim 1 , wherein the medical condition is selected from the group consisting of schizophrenia, psychosis, and depression.